Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may catch pelvic cancer relapse sooner

NCT ID NCT03739775

Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study looks at whether a blood test that detects tumor DNA can find early signs of cancer returning in people treated for HPV-positive pelvic cancers (like cervical or anal cancer). Researchers will take blood samples from 172 patients during regular follow-up visits. The goal is to see how well this test works at spotting relapses before symptoms appear.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this blood test could help catch cancer relapses earlier, potentially improving treatment outcomes.
What could go wrong
This is an observational study, not a treatment trial. The test may not be accurate enough for routine use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

172 people

The number who actually took part.

Started

Jan 2019

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 1\) Patient curatively treated within the past 3 years for: * a HPV-induced stage Ib3, Ic, II or III cervix cancer * a HPV-induced stage II or III anal canal, vagina, vulva or penis cancer 2. Patient with no evidence of any invasive tumor at inclusion (clinical and, if any, radiological exams). 3. Age ≥ 18 years 4. Availability of HPV genotyping of the treated cancer and/or archived tumor tissue available. 5. Patient who a follow-up visit is scheduled in the including center at least twice a year. 6. Patient being affiliated to the French social security. 7. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Patient presenting with active invasive tumor masses (e.g. stage IV cancer). 2. Patient deprived from ability to decide on her own or placed under the authority of a tutor. 3. Patient unable to have a regular follow up for geographical, social or psychological reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV positive pelvic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal canal cancer anal canal squamous cell carcinoma cervical carcinoma human papillomavirus-related penile squamous cell carcinoma penile cancer vaginal cancer vaginal carcinoma vulva cancer vulvar carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV positive pelvic cancer

Contacts and locations

Locations

  • CHU Pontchaillou

    Rennes, 35033, France

  • CHU de Besançon

    Besançon, 25030, France

  • Hôpital Tenon

    Paris, 75020, France

  • Institut Curie - Paris

    Paris, 75005, France

  • Institut Curie - Saint-Cloud

    Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.